OPRX OptimizeRx Corp

OptimizeRx CEO, William Febbo, to Speak at Bank of America 4th Annual HCIT and Digital Health Symposium Today, December 9, 2020

OptimizeRx CEO, William Febbo, to Speak at Bank of America 4th Annual HCIT and Digital Health Symposium Today, December 9, 2020

ROCHESTER, Mich., Dec. 09, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has been invited to participate at the Bank of America 4th Annual HCIT and Digital Health Symposium on December 9-10.

OptimizeRx CEO William Febbo will be a speaker on the panel, “Trends in Tech-Enabled Rx Supply Chain.” The panel will be moderated by Rajat Bhatia, a Director in Global Healthcare Investment Banking at BofA Securities, and Justin Walter, Head of Healthcare Services Investment Banking at BofA Securities.

Event attendees will include healthcare-focused Bank of America corporate and commercial clients, executives from healthcare services and digital health companies, as well as private equity, venture capital and crossover equity investors.

About OptimizeRx

OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the US and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement.



For more information, follow the company on ,  or visit . 

Important Cautions Regarding Forward Looking Statements

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other material risks.

Company Contact

Doug Baker, CFO

Tel (248) 651-6568 x807

Media Contact

Maira Alejandra, Media Relations Manager

Tel (754) 245-7070

Investor Relations Contact

Ron Both or Grant Stude

CMA Investor Relations

Tel (949) 432-7557



EN
09/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OptimizeRx Corp

 PRESS RELEASE

OptimizeRx Reports Second Quarter 2025 Financial Results and Updates F...

OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance Q2 revenue of $29.2 million, increased 55% year-over-yearQ2 gross profit increased 59% year-over-year to $18.6 millionPaid down $4.5 million of principal on outstanding term loan during Q2Increased full year 2025 guidance to a revenue range between $104 million and $108 million and adjusted EBITDA range between $14.5 million and $17.5 million WALTHAM, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technolo...

 PRESS RELEASE

OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025...

OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025, at 4:30 p.m. ET WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, August 7, 2025, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will...

 PRESS RELEASE

OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Direct...

OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Directors WALTHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Steve Silvestro, currently serving as the Company’s Chief Executive Officer, to its Board of Directors, effective as of June 20, 2025. Mr. Silvestro joined the Company in 2019 and has been the Company’s CEO since March 2025, after serving as the interim...

 PRESS RELEASE

OptimizeRx to Participate in Upcoming Investor Conferences

OptimizeRx to Participate in Upcoming Investor Conferences WALTHAM, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: B. Riley Securities 25th Annual Investor Conference, Marina del Rey, May 21 – 22, 2025Stifel 2025 Boston Cross Sector 1x1 Conference, Boston, June 3 – 4, 202545th Annual William Blair Growth ...

 PRESS RELEASE

OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fi...

OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance Q1 revenue of $21.9 million, increasing 11% year-over-yearQ1 gross profit increased 9% year-over-year to $13.3 millionIncreases full year 2025 guidance to a revenue range between $101 million and $106 million and adjusted EBITDA range between $13 million and $15 million WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HC...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch